The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Yevgeniy Balagula, Steven T. Rosen, Mario E. Lacouture

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

Original languageEnglish (US)
Pages (from-to)624-635
Number of pages12
JournalJournal of the American Academy of Dermatology
Volume65
Issue number3
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Health
Neoplasms
Radiation
Skin
Therapeutics

Keywords

  • chemotherapy-induced alopecia
  • CIA
  • EGFR
  • EGFRI
  • epidermal growth factor receptor
  • epidermal growth factor receptor inhibitor
  • FDA
  • Food and Drug Administration
  • hand-foot skin reaction
  • hand-foot syndrome
  • HFS
  • HFSR
  • MASCC
  • Multinational Association for Supportive Care in Cancer
  • QoL
  • quality of life
  • randomized controlled trial
  • RCT

ASJC Scopus subject areas

  • Dermatology

Cite this

The emergence of supportive oncodermatology : The study of dermatologic adverse events to cancer therapies. / Balagula, Yevgeniy; Rosen, Steven T.; Lacouture, Mario E.

In: Journal of the American Academy of Dermatology, Vol. 65, No. 3, 09.2011, p. 624-635.

Research output: Contribution to journalArticle

@article{c9f8c24fbf36470bb0fd4a2e669830ee,
title = "The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies",
abstract = "Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.",
keywords = "chemotherapy-induced alopecia, CIA, EGFR, EGFRI, epidermal growth factor receptor, epidermal growth factor receptor inhibitor, FDA, Food and Drug Administration, hand-foot skin reaction, hand-foot syndrome, HFS, HFSR, MASCC, Multinational Association for Supportive Care in Cancer, QoL, quality of life, randomized controlled trial, RCT",
author = "Yevgeniy Balagula and Rosen, {Steven T.} and Lacouture, {Mario E.}",
year = "2011",
month = "9",
doi = "10.1016/j.jaad.2010.06.051",
language = "English (US)",
volume = "65",
pages = "624--635",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The emergence of supportive oncodermatology

T2 - The study of dermatologic adverse events to cancer therapies

AU - Balagula, Yevgeniy

AU - Rosen, Steven T.

AU - Lacouture, Mario E.

PY - 2011/9

Y1 - 2011/9

N2 - Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

AB - Cancer therapies have led to remarkable results due to improved toxicity profiles and effects on survival. While these medical, surgical, and radiation protocols are chiefly responsible for these noteworthy contributions, an unexpected constellation of toxicities has emerged. Most notably, dermatologic adverse events have gained considerable attention, due to their high frequency, visibility, and impact on physical and psychosocial health, all of which affect dose intensity and possibly clinical outcome. Consequently, increased attention to cutaneous health in oncology has resulted in supportive oncodermatology clinical programs and toxicity-driven investigations, aiming to mitigate these untoward events and permit the continued optimization of cancer treatments.

KW - chemotherapy-induced alopecia

KW - CIA

KW - EGFR

KW - EGFRI

KW - epidermal growth factor receptor

KW - epidermal growth factor receptor inhibitor

KW - FDA

KW - Food and Drug Administration

KW - hand-foot skin reaction

KW - hand-foot syndrome

KW - HFS

KW - HFSR

KW - MASCC

KW - Multinational Association for Supportive Care in Cancer

KW - QoL

KW - quality of life

KW - randomized controlled trial

KW - RCT

UR - http://www.scopus.com/inward/record.url?scp=80051798682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051798682&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.06.051

DO - 10.1016/j.jaad.2010.06.051

M3 - Article

C2 - 21777992

AN - SCOPUS:80051798682

VL - 65

SP - 624

EP - 635

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -